Adlai Nortye Ltd.

NASDAQ:ANL

Biotechnology

Healthcare
$8.74 -1.07%

-$0.11 today

Market cap
$463.92M
Beta
0.99
P/E (TTM)
-3.0
EPS (TTM)
-$3.33
52W Low $0.88High $17.25

Volume 0.45M

Average 0.35M

ANL Interest Income

Income earned on cash, deposits, and investments held by the company.

Adlai Nortye Ltd.NASDAQ: ANL

Interest Income · Q2 FY2024 · quarter ended Jun 2024

Interest income growth accelerates

Q2 FY2024 interest income of $472K rose 187.8% year over year, ahead of the +183.8% change in trailing-twelve-month interest income. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -87.8% a year.

Context

  • Interest income amounted to 0.0% of revenue in FY2025.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +187.8% holds above the trailing-twelve-month pace of +183.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2024
$472K+0.0% QoQ
Last fiscal yearDec 2025
$1K— YoY
LTMJun 2024
$1.49M+183.8% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+187.8%——
1 year———
3-year CAGR-87.8%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
1K USD
Year-over-year change
—
4-year CAGR
-57.9%

Interest Income vs competitors

How ANL compares with its peers on the latest reported figures

  • ANL's LTM Jun 2024 interest income of $1.49M is the 5th highest of the 7 companies compared; the peer median is $3.53M.
  • Interest income amounts to 23.0% of revenue for ANL, versus a peer median of 8.9%.
ANL Competitors Peer median
Interest Income for ANL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NUVBNuvation Bio Inc.LTM Jun 2026$21.03M -8.1%+42.2%12.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.8M -35.9%+15.5%27.6%
VSTMVerastem, Inc.LTM Mar 2026$4.4M +17.7%+49.6%8.9%
CGENCompugen Ltd.LTM Mar 2026$2.66M -49.0%+45.3%3.7%
ANLAdlai Nortye Ltd.LTM Jun 2024$1.49M —-87.8%23.0%
APLMApollomics, Inc.FY2025$152K -68.3%-29.3%1.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$525K -125.8%+56.5%—
Peer median (excluding ANL) $3.53M-42.4%+43.8%8.9%

Competitors are the stored peer set for ANL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.73M0005M
Cost of Revenue00000
Gross Profit45.73M0005M
Gross Margin100.0%———100.0%
Research & Development42.11M54.49M58.15M44.92M32.83M
Selling, General & Admin12.45M12.43M14.82M9.44M7.79M
Operating Expenses54.37M67.27M72.55M52.93M40.7M
Depreciation & Amortization1.83M2.04M2.22M1.87M1.41M
EBITDA(53.51M)(56.32M)(106.22M)(48.06M)(32.63M)
EBITDA Margin-117.0%———-652.5%
Operating Income(8.65M)(67.27M)(72.55M)(52.93M)(35.7M)
Operating Margin-18.9%———-714.0%
Interest Income32K550K62K01K
Interest Expense1.34M433K791K1.94M1.49M
Other Income / Expenses(48.03M)8.48M(36.68M)1.06M170K
Income Before Tax(56.68M)(58.79M)(109.23M)(51.87M)(35.53M)
Pre-Tax Margin-124.0%———-710.6%
Income Tax Expense00000
Net Income(56.68M)(58.79M)(109.23M)(51.87M)(35.53M)
Net Margin-124.0%———-710.6%
EPS (Basic)(6.66)(6.93)(15.42)(4.89)(3.33)
EPS (Diluted)(6.66)(6.93)(15.42)(4.89)(3.33)
Weighted Avg Shares8.48M8.48M6.8M10.64M10.66M
Weighted Avg Shares (Diluted)8.48M8.48M6.8M10.64M10.66M

Adlai Nortye Ltd.

NASDAQ:ANL

Intrinsic Alpha fair value

Locked

Current Price

$8.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.